Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 12/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 12/20 | 0.35 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22681422 | 0.76 | P2RX3 (0.44) | P2RX3P2RX2ACVR2ATGFBR2SMPD3 | |
| SCHEMBL21030294 | 0.76 | P2RX3 (0.37) | P2RX3P2RX2ACVR2ATGFBR2SMPD3 | |
| SCHEMBL21101202 | 0.76 | KMT2A (0.36) | NUDT1KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL14997537 | 0.76 | — | — | |
| SCHEMBL19523196 | 0.76 | P2RX3 (0.37) | P2RX3P2RX2ACVR2ATGFBR2SMPD3 | |
| SCHEMBL26022485 | 0.75 | ASPH (0.31) | — | |
| SCHEMBL21030194 | 0.74 | SMPD3 (0.40) | P2RX3P2RX2ACVR2ATGFBR2SMPD3 | |
| SCHEMBL10220470 | 0.74 | GAA (0.33) | — | |
| SCHEMBL10220792 | 0.74 | MAPT (0.42) | NUDT1KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL14997539 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | SLC10A1, CYP7A1, FABP1 | P2RX3 3261/4885P2RX2 3674/4885ACVR2A 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.